By interacting with the p110α catalytic subunit of phosphoinositide 3-kinase (PI3K), KRAS can cause constitutive activation of oncogenic PI3K–protein kinase B (Akt) signaling and promote the progression of lung cancer [18]. The gene discussed is AKT1; the disease is lung carcinoma.